PT - JOURNAL ARTICLE AU - Koprulu, Mine AU - Zhao, Yajie AU - Wheeler, Eleanor AU - Dong, Liang AU - Rocha, Nuno AU - Patel, Satish AU - Van de Streek, Marcel AU - Glastonbury, Craig A. AU - Stewart, Isobel D. AU - Day, Felix R. AU - Luan, Jian’an AU - Bowker, Nicholas AU - Wittemans, Laura B. L. AU - Kerrison, Nicola D. AU - Lucarelli, Debora M. E. AU - Barroso, Inês AU - McCarthy, Mark I. AU - Scott, Robert A. AU - Saudek, Vladimir AU - Small, Kerrin S. AU - Wareham, Nicholas J. AU - Semple, Robert K. AU - Perry, John R. B. AU - O’Rahilly, Stephen AU - Lotta, Luca A. AU - Langenberg, Claudia AU - Savage, David B. TI - Identification of rare loss of function variation regulating body fat distribution AID - 10.1101/2021.09.11.21263427 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.11.21263427 4099 - http://medrxiv.org/content/early/2021/09/15/2021.09.11.21263427.short 4100 - http://medrxiv.org/content/early/2021/09/15/2021.09.11.21263427.full AB - Biological and translational insights from large-scale, array-based genetic studies of fat distribution, a key determinant of metabolic health, have been limited by the difficulty in linking identified predominantly non-coding variants to specific gene targets. Rare coding variant analyses provide greater confidence that a specific gene is involved, but do not necessarily indicate whether gain or loss of function would be of most therapeutic benefit. Here we use a dual approach that combines the power of genome-wide analysis of array-based rare, non-synonymous variants in 184,246 individuals of UK Biobank with exome-sequence-based rare loss of function gene burden testing. The data indicates that loss-of-function (LoF) of four genes (PLIN1, INSR, ACVR1C and PDE3B) is associated with a beneficial impact on WHRadjBMI and increased gluteofemoral fat mass, whereas PLIN4 LoF adversely affects these parameters. This study robustly implicates these genes in the regulation of fat distribution, providing new and in some cases somewhat counter-intuitive insight into the potential consequences of targeting these molecules therapeutically.Competing Interest StatementM.McM. is an employee of Genentech, and a holder of Roche stock. D.M.E.L. is currently an employee of Enhanc3D Genomics Ltd. N.B. is an employee of GlaxoSmithKline Plc. (GSK). R.A.S. is an employee and shareholder of GlaxoSmithKline Plc. (GSK). C.A.G. is an employee of Benevolent AI. L.A.L. is an employee of Regeneron Genetics Center and receives salary, stocks and stock options from Regeneron Pharmaceuticals Inc. Funding StatementThis study was funded by the United Kingdom's Medical Research Council through grants MC_UU_12015/1, MC_PC_13046, MC_PC_13048 and MR/L00002/1. This work was supported by the MRC Metabolic Diseases Unit (MC_UU_12012/5) and the Cambridge NIHR Biomedical Research Centre and EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant: 115372). R.K.S, D.B.S. and S.O'R. are supported by the Wellcome Trust (WT 210752, WT 219417 and WT 214274 respectively) the MRC Metabolic Disease Unit, the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Rare Disease Translational Research Collaboration. K.S.S. is supported by MRC Project Grant L01999X/1. Some computation was enabled through access granted to K.S.S. to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council (grant number MR/L016311/1). M.McC. is a Wellcome Senior Investigator supported by Wellcome grants 098381, 090532, 106130, 203141. M.McC. declares that the views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health; he has served on advisory panels for Pfizer, Novo Nordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. M.K. is supported by the Gates Cambridge Trust. The authors gratefully acknowledge the help of the MRC Epidemiology Unit Support Teams, including Field, Laboratory and Data Management Teams.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis research has been conducted using the UK Biobank resource (application no. 44448 and 9905). Access to the UK Biobank genotype and phenotype data is open to all approved health researchers (http://www.ukbiobank.ac.uk/). http://www.ukbiobank.ac.uk/